Availability
0
Your Basket is Empty
FA18068
BIO-X

AZD 8055

A selective and ATP-competitive inhibitor of mTOR kinase with an IC50 value of 0.8 nM. Inhibits growth of a range of tumor types in vivo and in vitro. Effective in preventing and treating endocrine-resistant breast cancer. Causes autophagy in H838 and A549 cells.

Technical Data

CAS No: 1009298-09-2
Synonyms: 5-[2,4-Bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxybenzenemethanol; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]- 2-methoxyphenyl]methanol
Product Code: FA18068
MDL No: MFCD16660191
Chemical Formula: C25H31N5O4
Molecular Weight: 465.54

References


  • Chresta et al (2010). AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70(1):288-98.
  • Sini P et al (2010). Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 6(4):553-4.
  • Jordan NJ et al (2014). Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res 16(1):R12.

Solubility

Stability

Further Information


Datasheets

Specification: View

CAS No:
1009298-09-2
Synonyms:
5-[2,4-Bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxybenzenemethanol
[5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]- 2-methoxyphenyl]methanol
MDL No:
MFCD16660191
Chemical Formula:
Molecular Weight:
465.54
Product Structure
References:
1. Chresta et al (2010). AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70(1):288-98.
2. Sini P et al (2010). Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 6(4):553-4.
3. Jordan NJ et al (2014). Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res 16(1):R12.
Click for Specification

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...